Cargando…

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma

Recent studies have demonstrated that HER2 and MET receptor tyrosine kinases are co-overexpressed in a subset esophageal adenocarcinoma (EAC). We therefore studied the usefulness of combining HER2 and MET targeting by small-molecule inhibitors lapatinib and foretinib, respectively, both in in-vitro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hassan, Md. Sazzad, Williams, Fiona, Awasthi, Niranjan, Schwarz, Margaret A., Schwarz, Roderich E., Li, Jun, von Holzen, Urs
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6879590/ https://www.ncbi.nlm.nih.gov/pubmed/31772236 http://dx.doi.org/10.1038/s41598-019-54129-7

Ejemplares similares

Targeted dual inhibition of c‐Met/VEGFR2 signalling by foretinib improves antitumour effects of nanoparticle paclitaxel in gastric cancer models
por: Grojean, Meghan, et al.
Publicado: (2021)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2017)

Cytokine Interaction With Cancer-Associated Fibroblasts in Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2022)

Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review)
por: Zhang, Joshua, et al.
Publicado: (2023)

Therapeutic Potential of the Cyclin-Dependent Kinase Inhibitor Flavopiridol on c-Myc Overexpressing Esophageal Cancer
por: Hassan, Md Sazzad, et al.
Publicado: (2021)

Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
por: Hassan, Md Sazzad, et al.
Publicado: (2023)

Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
por: Simiczyjew, Aleksandra, et al.
Publicado: (2018)

Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met
por: Chen, Guang-Zong, et al.
Publicado: (2017)

Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018)

Validated liquid chromatography tandem mass spectrometry for simultaneous quantification of foretinib and lapatinib, and application to metabolic stability investigation
por: Alanazi, Mohammed M., et al.
Publicado: (2019)

A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer
por: Chia, Stephen K., et al.
Publicado: (2017)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021)

Profile of nintedanib in the treatment of solid tumors: the evidence to date
por: Awasthi, Niranjan, et al.
Publicado: (2015)

The dual PI3K/mTOR inhibitor NVP-BEZ235 enhances nab-paclitaxel antitumor response in experimental gastric cancer
por: ZHANG, CHANG-HUA, et al.
Publicado: (2013)

Cell Proliferation and Migration Are Modulated by Cdk-1-Phosphorylated Endothelial-Monocyte Activating Polypeptide II
por: Schwarz, Margaret A., et al.
Publicado: (2012)

Evaluation of Poly-Mechanistic Antiangiogenic Combinations to Enhance Cytotoxic Therapy Response in Pancreatic Cancer
por: Awasthi, Niranjan, et al.
Publicado: (2012)

Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II
por: Awasthi, Niranjan, et al.
Publicado: (2013)

Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer
por: Zhang, Changhua, et al.
Publicado: (2013)

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2017)

Foretinib Inhibits Cancer Stemness and Gastric Cancer Cell Proliferation by Decreasing CD44 and c-MET Signaling
por: Sohn, Sung-Hwa, et al.
Publicado: (2020)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

56. Foretinib Enhances Myelination of Neurons in Vitro
por: Mirmoeini, Kaveh, et al.
Publicado: (2023)

Enhancing gastric cancer conventional chemotherapy effects by triple angiokinase inhibitor nintedanib in preclinical models
por: Awasthi, Niranjan, et al.
Publicado: (2023)

National Economic Conditions May Impact the Financial Barriers to Travel for Cancer Operations
por: Henry, Leonard R., et al.
Publicado: (2023)

Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2011)

Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models
por: Awasthi, Niranjan, et al.
Publicado: (2016)

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation
por: Fujino, Toshio, et al.
Publicado: (2022)

The role of HGF/MET and FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma
por: Saito, Shin, et al.
Publicado: (2015)

Therapeutic efficacy of anti‐MMP9 antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical models of pancreatic cancer
por: Awasthi, Niranjan, et al.
Publicado: (2019)

FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation
por: Park, Jinju, et al.
Publicado: (2018)

Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma
por: Fu, Yuyin, et al.
Publicado: (2021)

Foretinib mitigates cutaneous nerve fiber loss in experimental diabetic neuropathy
por: Daeschler, Simeon C., et al.
Publicado: (2022)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer
por: Cristofanilli, Massimo, et al.
Publicado: (2012)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling
por: Ji, Xiwei, et al.
Publicado: (2023)

Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer
por: Leung, Wing-yin, et al.
Publicado: (2015)

Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor
por: Spector, Neil L., et al.
Publicado: (2015)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants
por: Verma, Sharad, et al.
Publicado: (2018)

Foretinib (GSK1363089) induces p53-dependent apoptosis in endometrial cancer
por: Kogata, Yuhei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qf33k7ns8njspi511ahk3576nc